•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) said 17 clinical advances from its core assets will be featured at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The abstracts include data from ongoing clinical studies of Olverembatinib (HQP1351) and Lisaftoclax (APG-2575). EHA2026 will be held in Stockholm, Sweden, from June 11 to 14, 2026.
All abstracts (including posters and publication-only submissions) are available on the EHA website.
Ascentage said Olverembatinib and Lisaftoclax are currently under investigation and have not yet been approved by the FDA in the US.
Olverembatinib is described as China’s first approved third-generation BCR-ABL inhibitor. Lisaftoclax is described as the first approved China-developed Bcl-2 selective inhibitor.
Ascentage Pharma Group International is a global, commercial-stage, integrated biopharmaceutical company focused on the discovery, development and commercialization of differentiated therapies for unmet medical needs in cancer. The company’s pipeline includes inhibitors targeting proteins in the apoptotic pathway, including Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.
The company’s first approved product, Olverembatinib, is described as the first novel third-generation BCR-ABL1 inhibitor approved in China for treatment of chronic-phase CML (CML-CP) with T315I mutations, accelerated-phase CML (CML-AP) with T315I mutations, and CML-CP resistant or intolerant to first- and second-generation TKIs. It is covered by China’s National Reimbursement Drug List (NRDL). Ascentage is conducting an FDA-cleared registrational Phase III trial, POLARIS-2, for CML, and registrational Phase III trials for newly diagnosed Ph+ ALL (POLARIS-1) and SDH-deficient GIST (POLARIS-3).
Ascentage’s second approved product, Lisaftoclax, is described as a Bcl-2 inhibitor approved in China for adult patients with CLL/SLL who have previously received at least one systemic therapy, including BTK inhibitors. The company said it is conducting four global registrational Phase III trials: GLORA (FDA-cleared) in combination with BTK inhibitors for CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; GLORA-2 in newly diagnosed CLL/SLL; GLORA-3 in newly diagnosed, elderly and unfit patients with AML; and GLORA-4 (FDA-cleared) in newly diagnosed higher-risk MDS.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
